Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy

Byung Il Yeh, KwangHyub Han, Seung Hee Oh, Hyon Suk Kim, Suk Hyun Hong, Sang Hwan Oh, Yoon Soo Kim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Ten patients with hepatitis C virus (HCV) infection (experimental group) were treated with interferon-α (IF-α). Dosage was six million units per day for one week and then three times a week for another six months. Seven HCV-infected patients (control group) did not receive IF-α therapy. The hypervariable region (HVR) of HCV in the sera of patients was amplified by reverse trancription-polymerase chain reaction (RT-PCR), and the variation of amino acid sequence in this region was determined. Serum alanine aminotransferase (ALT) activities in five patients treated for six months with IF-α fell to the normal range, when HCV was not detected in the sera of three patients. The nucleotide sequence variation in HVR of HCV in the sera of five patients who responded well to the IF-α. therapy was relatively less than that in another five patients who did not respond to IF-α therapy and those in the control patients. These results indicate that the effectiveness of IF-α therapy was related to the sequence variation of HVR of HCV. This may have resulted from the selection pressure by humoral antibodies directed to HVR of HCV. It is concluded that the higher rate of sequence variation in HVR of HCV was compatible with a lower degree of effectiveness of IF-α therapy.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalJournal of Medical Virology
Volume49
Issue number2
DOIs
Publication statusPublished - 1996 Jun 1

Fingerprint

Chronic Hepatitis C
Hepacivirus
Interferons
Serum
Therapeutics
Virus Diseases
Alanine Transaminase
Amino Acid Sequence
Reference Values
Pressure
Polymerase Chain Reaction
Control Groups
Antibodies

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

@article{2332304232cf43608c888204c3d3f6e3,
title = "Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy",
abstract = "Ten patients with hepatitis C virus (HCV) infection (experimental group) were treated with interferon-α (IF-α). Dosage was six million units per day for one week and then three times a week for another six months. Seven HCV-infected patients (control group) did not receive IF-α therapy. The hypervariable region (HVR) of HCV in the sera of patients was amplified by reverse trancription-polymerase chain reaction (RT-PCR), and the variation of amino acid sequence in this region was determined. Serum alanine aminotransferase (ALT) activities in five patients treated for six months with IF-α fell to the normal range, when HCV was not detected in the sera of three patients. The nucleotide sequence variation in HVR of HCV in the sera of five patients who responded well to the IF-α. therapy was relatively less than that in another five patients who did not respond to IF-α therapy and those in the control patients. These results indicate that the effectiveness of IF-α therapy was related to the sequence variation of HVR of HCV. This may have resulted from the selection pressure by humoral antibodies directed to HVR of HCV. It is concluded that the higher rate of sequence variation in HVR of HCV was compatible with a lower degree of effectiveness of IF-α therapy.",
author = "Yeh, {Byung Il} and KwangHyub Han and Oh, {Seung Hee} and Kim, {Hyon Suk} and Hong, {Suk Hyun} and Oh, {Sang Hwan} and Kim, {Yoon Soo}",
year = "1996",
month = "6",
day = "1",
doi = "10.1002/(SICI)1096-9071(199606)49:2<95::AID-JMV5>3.0.CO;2-E",
language = "English",
volume = "49",
pages = "95--102",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy. / Yeh, Byung Il; Han, KwangHyub; Oh, Seung Hee; Kim, Hyon Suk; Hong, Suk Hyun; Oh, Sang Hwan; Kim, Yoon Soo.

In: Journal of Medical Virology, Vol. 49, No. 2, 01.06.1996, p. 95-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nucleotide sequence variation in the hypervariable region of the hepatitis C virus in the sera of chronic hepatitis C patients undergoing controlled interferon-α therapy

AU - Yeh, Byung Il

AU - Han, KwangHyub

AU - Oh, Seung Hee

AU - Kim, Hyon Suk

AU - Hong, Suk Hyun

AU - Oh, Sang Hwan

AU - Kim, Yoon Soo

PY - 1996/6/1

Y1 - 1996/6/1

N2 - Ten patients with hepatitis C virus (HCV) infection (experimental group) were treated with interferon-α (IF-α). Dosage was six million units per day for one week and then three times a week for another six months. Seven HCV-infected patients (control group) did not receive IF-α therapy. The hypervariable region (HVR) of HCV in the sera of patients was amplified by reverse trancription-polymerase chain reaction (RT-PCR), and the variation of amino acid sequence in this region was determined. Serum alanine aminotransferase (ALT) activities in five patients treated for six months with IF-α fell to the normal range, when HCV was not detected in the sera of three patients. The nucleotide sequence variation in HVR of HCV in the sera of five patients who responded well to the IF-α. therapy was relatively less than that in another five patients who did not respond to IF-α therapy and those in the control patients. These results indicate that the effectiveness of IF-α therapy was related to the sequence variation of HVR of HCV. This may have resulted from the selection pressure by humoral antibodies directed to HVR of HCV. It is concluded that the higher rate of sequence variation in HVR of HCV was compatible with a lower degree of effectiveness of IF-α therapy.

AB - Ten patients with hepatitis C virus (HCV) infection (experimental group) were treated with interferon-α (IF-α). Dosage was six million units per day for one week and then three times a week for another six months. Seven HCV-infected patients (control group) did not receive IF-α therapy. The hypervariable region (HVR) of HCV in the sera of patients was amplified by reverse trancription-polymerase chain reaction (RT-PCR), and the variation of amino acid sequence in this region was determined. Serum alanine aminotransferase (ALT) activities in five patients treated for six months with IF-α fell to the normal range, when HCV was not detected in the sera of three patients. The nucleotide sequence variation in HVR of HCV in the sera of five patients who responded well to the IF-α. therapy was relatively less than that in another five patients who did not respond to IF-α therapy and those in the control patients. These results indicate that the effectiveness of IF-α therapy was related to the sequence variation of HVR of HCV. This may have resulted from the selection pressure by humoral antibodies directed to HVR of HCV. It is concluded that the higher rate of sequence variation in HVR of HCV was compatible with a lower degree of effectiveness of IF-α therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029989728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029989728&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9071(199606)49:2<95::AID-JMV5>3.0.CO;2-E

DO - 10.1002/(SICI)1096-9071(199606)49:2<95::AID-JMV5>3.0.CO;2-E

M3 - Article

VL - 49

SP - 95

EP - 102

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 2

ER -